[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperglycemia-due-to-type-2-diabetes-mellitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperglycemia-due-to-type-2-diabetes-mellitus":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100651260","phase-1-pre-emptive-insulin-to-prevent-high-glucose-after-a-knee-steroid-injection-in-adults-with-type-2-diabetes-100651260",false,"NCT07757464","Pre-emptive Insulin to Prevent High Glucose After a Knee Steroid Injection in Adults With Type 2 Diabetes","A Phase 2 Randomized Trial of Pre-emptive NPH Insulin Versus Usual Reactive Diabetes Management for Preventing Hyperglycaemia After Intra-articular Triamcinolone Acetonide Injection in Adults With Type 2 Diabetes and Knee Osteoarthritis","PREVENT-SIH","Inclusion Criteria:\n\n* Age 40 to 80 years at consent.\n* Documented diagnosis of type 2 diabetes for at least 6 months.\n* HbA1c from 6.5% through 9.0% measured within 30 days before randomisation.\n* Symptomatic osteoarthritis of one knee for which the treating clinician has independently determined that an intra-articular corticosteroid injection is clinically indicated.\n* Planned administration of one intra-articular injection of triamcinolone acetonide crystalline suspension 40 mg into the index knee.\n* Diabetes managed without insulin, sulfonylureas or meglitinides.\n* Permitted glucose-lowering medications at stable doses for at least 30 days before randomisation.\n* Estimated glomerular filtration rate at least 45 mL\u002Fmin\u002F1.73 m² within 60 days before randomisation.\n* Capillary glucose from 90 through 250 mg\u002FdL immediately before the injection.\n* Ability and willingness to perform scheduled capillary glucose testing, administer or receive subcutaneous insulin if assigned, follow hypoglycaemia instructions and remain contactable through day 7.\n* Ability to wear the study continuous glucose monitoring device and provide informed consent.\n\nExclusion Criteria:\n\n* Type 1 diabetes, latent autoimmune diabetes in adults, pancreatogenic diabetes or another specific diabetes type requiring insulin.\n* Current basal, prandial, premixed or pump insulin treatment.\n* Current sulfonylurea or meglitinide treatment.\n* HbA1c below 6.5% or above 9.0%.\n* Capillary glucose below 90 mg\u002FdL or above 250 mg\u002FdL immediately before injection.\n* Fasting glucose above 250 mg\u002FdL, random glucose above 300 mg\u002FdL, clinically significant ketonaemia or hyperglycaemia requiring immediate treatment during screening.\n* Estimated glomerular filtration rate below 45 mL\u002Fmin\u002F1.73 m².\n* Severe hepatic impairment or another condition expected to materially alter insulin clearance or hypoglycaemia risk.\n* Level 3 hypoglycaemia requiring third-party assistance during the previous 6 months.\n* Documented impaired awareness of hypoglycaemia.\n* Pregnancy, planned pregnancy during study participation or breastfeeding.\n* Oral, intravenous or intramuscular corticosteroid use within 30 days before the study injection.\n* Any intra-articular, epidural, periarticular or soft-tissue corticosteroid injection within 30 days before the study injection.\n* Planned additional systemic or injected corticosteroid exposure before the day-7 assessment.\n* Acute febrile illness, active systemic infection or acute deterioration in health at screening or injection.\n* Suspected septic arthritis, infection over the injection site, prosthetic index knee, uncontrolled bleeding disorder or another contraindication to knee injection.\n* Known allergy or clinically significant hypersensitivity to triamcinolone acetonide, human NPH insulin, insulin aspart, protamine, lidocaine or required excipients.\n* Known allergy to continuous glucose monitoring adhesive or a skin condition preventing sensor use.\n* Cognitive, visual, physical or social limitation that would prevent safe glucose testing, insulin administration, hypoglycaemia treatment or study contact.\n* Participation in another interventional study likely to affect glucose or corticosteroid response.\n* Any condition that, in the investigator's documented judgement, makes participation unsafe for a reason not otherwise captured above.","ALL","40 Years","80 Years",{"count":21,"type":22},125,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Steroid injections used to treat painful joints can temporarily increase glucose levels in people with type 2 diabetes. This study will test whether a short course of pre-emptive neutral protamine Hagedorn, NPH, insulin can reduce high glucose after a standard corticosteroid injection into the knee.\n\nAdults with type 2 diabetes who are scheduled to receive one intra-articular injection of triamcinolone acetonide 40 mg for knee osteoarthritis will be randomly assigned to one of two groups. The experimental group will receive a prespecified NPH insulin regimen beginning immediately after the injection and continuing for three doses. The comparison group will continue usual reactive diabetes management without pre-emptive NPH insulin.\n\nBoth groups will use blinded continuous glucose monitoring and scheduled capillary glucose testing. The main outcome is the percentage of continuous glucose monitoring time above 180 mg\u002FdL during the first 72 hours after the corticosteroid injection. Hypoglycaemia, rescue treatment, healthcare contacts, treatment burden, acceptability and adverse events will also be assessed.",[29,30,31],"Diabetes Mellitus, Type 2","Hyperglycemia Due to Type 2 Diabetes Mellitus","Osteoarthritis, Knee",[33,34,35,36,37,38,39],"Steroid-induced hyperglycaemia","Glucocorticoid-induced hyperglycaemia","Intra-articular corticosteroid injection","Triamcinolone acetonide","NPH insulin","Continuous glucose monitoring","Knee osteoarthritis","NOT_YET_RECRUITING","2026-08-05",{"date":43,"type":44},"2026-08-11","ACTUAL",{"date":46,"type":22},"2026-08-10",{"date":48,"type":22},"2027-01-30",{"name":50,"class":51},"Shifa International Hospital","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100648906","multilingual-voice-calls-to-adjust-long-acting-insulin-for-adults-with-type-2-diabetes-and-low-health-literacy-in-pakistan-100648906","NCT07729501","Multilingual Voice Calls to Adjust Long-Acting Insulin for Adults With Type 2 Diabetes and Low Health Literacy in Pakistan","Multilingual Voice-Based Insulin Titration for Adults With Type 2 Diabetes and Low Health Literacy in Pakistan: A Randomized Trial","VOICE-TITR-PK","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosed with type 2 diabetes mellitus.\n* Currently receiving basal insulin or considered by the treating clinician to require initiation or adjustment of basal insulin.\n* Glycemic control considered inadequate and requiring basal insulin titration according to the study protocol.\n* Low health literacy as determined using the study-approved screening method.\n* Able to communicate in one of the languages supported by the study intervention.\n* Has access to a functioning feature phone or mobile telephone and is able to receive automated voice calls.\n* Able and willing to perform fasting blood glucose monitoring according to the study procedures.\n* Willing and able to provide informed consent.\n* Willing to comply with study procedures and complete the 12-week follow-up.\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus, gestational diabetes, or another specific form of diabetes other than type 2 diabetes mellitus.\n* Pregnancy, current breastfeeding, or planned pregnancy during the study period.\n* Current use of an insulin pump.\n* Severe hypoglycemia requiring assistance from another person within the period specified in the protocol before enrollment.\n* Recurrent hypoglycemia or another clinical condition that, in the investigator's judgment, makes protocol-directed insulin titration unsafe.\n* Acute metabolic decompensation, including diabetic ketoacidosis or hyperosmolar hyperglycemic state, at screening or within the period specified in the protocol.\n* Severe renal, hepatic, cardiac, psychiatric, cognitive, hearing, or other medical impairment that would prevent safe participation or completion of the voice-call intervention.\n* Inability to understand or respond to the study's supported voice-call languages.\n* Inability to use the telephone or glucose-monitoring procedures, with or without assistance permitted by the protocol.\n* Current participation in another interventional clinical trial that could interfere with the study outcomes.\n* Any other condition that, in the investigator's judgment, would make participation unsafe or compromise adherence to the study procedures.","18 Years",{"count":62,"type":22},220,[64],"NA","This study will evaluate whether a multilingual, feature-phone interactive voice response (IVR) system with human-verified basal insulin titration improves glycemic control compared with standard clinic-based insulin titration among adults with type 2 diabetes and low health literacy in Pakistan. Approximately 220 participants will be randomly assigned to either the IVR-supported titration strategy or usual clinic-based care. Participants will be followed for 12 weeks, with the primary outcome being change in glycated hemoglobin (HbA1c) from baseline to Week 12. Secondary outcomes include fasting plasma glucose, insulin dose adjustment, hypoglycemia, treatment adherence, patient satisfaction, health literacy-related outcomes, and implementation measures.",[67,30],"Type 2 Diabetes Mellitus (T2DM)",[69,70,71,72,73,74,75,76,77,78],"Type 2 Diabetes Mellitus","Basal Insulin","Insulin Titration","Interactive Voice Response","Telemedicine","Mobile Health","Digital Health","Health Literacy","Glycemic Control","Pakistan","2026-07-26",{"date":81,"type":44},"2026-07-28",{"date":83,"type":22},"2026-09-25",{"date":85,"type":22},"2027-03-01",{"name":50,"class":51},1]